Categories AlphaGraphs, Earnings, Technology
Earnings: Highlights of International Business Machines (IBM) Q2 results
International Business Machines Corporation (NYSE: IBM) on Wednesday announced operating results for the second quarter of 2023, reporting a decline in adjusted earnings.
Total revenues were $15.5 billion in the second quarter of 2023, which is broadly unchanged from the prior-year period. Meanwhile, adjusted earnings from continuing operations declined to $2.18 per share from $2.31 per share in the year-ago period. On an unadjusted basis, June-quarter net profit was $1.58 billion or $1.72 per share, compared to $1.39 billion or $1.53 per share in the corresponding period of 2022.
“We continue to respond to the needs of our clients who seek trusted, enterprise AI solutions, and we are particularly excited about the response to the recently launched watsonx AI platform. Finally, we remain confident in our revenue and free cash flow growth expectations for the full year,” said IBM’s CEO Arvind Krishna.
Prior Performance
_________________________________________________________________________________________________________________
Stocks you may like:
International Business Machines Corp. (IBM) Stock
_________________________________________________________________________________________________________________
Most Popular
Nike (NKE) looks set to beat hurdles and build a brighter future
Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business
Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company
Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as
Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor
Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications
